Supplemental Material: Histopathological predictors of immune-related adverse events among patients with melanoma treated with immune checkpoint inhibitors

Name: Supplemental Material: Histopathological predictors of immune-related adverse events among patients with melanoma treated with immune checkpoint inhibitors
Creator: Catherina Pan
Published: 2023-11-22T07:10:14.209Z
Keywords: Histopathology, Adverse Event, Melanoma, Immune Checkpoint Inhibitor

Pan, Catherina; Liu, Mofei; Lau, Charles; Lau, William; Kim, Daniel; Rowley, Rachael; Kanwar, Ruhi; Giobbie-Hurder, Anita; LeBoeuf, Nicole; Nambudiri, Vinod

doi:10.17632/nxp4xwy8hz.1

Supplemental Material: Histopathological predictors of immune-related adverse events among patients with melanoma treated with immune checkpoint inhibitors

Published: 22 November 2023| Version 1 | DOI: 10.17632/nxp4xwy8hz.1

Contributors:

Catherina Pan, Mofei Liu, Charles Lau, William Lau, Daniel Kim, Rachael Rowley, Ruhi Kanwar, Anita Giobbie-Hurder, Nicole LeBoeuf, Vinod Nambudiri

Description

Supplementary tables for JAAD research letter titled "Histopathological predictors of immune-related adverse events among patients with melanoma treated with immune checkpoint inhibitors"

Files

Institutions

Brigham and Women's Hospital, Boston University, Dana Farber Cancer Institute, Harvard Medical School, Boston University School of Medicine

Supplemental Material: Histopathological predictors of immune-related adverse events among patients with melanoma treated with immune checkpoint inhibitors

Description

Files

Institutions

Categories

Licence